VIVANI MED.INC. NEW O.N. (U5P) - Cash Flow Conversion Efficiency
Based on the latest financial reports, VIVANI MED.INC. NEW O.N. (U5P) has a cash flow conversion efficiency ratio of -0.427x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-6.72 Million ≈ $-7.86 Million USD) by net assets (€15.73 Million ≈ $18.39 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of VIVANI MED.INC. NEW O.N. for the company's overall valuation and market capitalisation.
VIVANI MED.INC. NEW O.N. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how VIVANI MED.INC. NEW O.N.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
VIVANI MED.INC. NEW O.N. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of VIVANI MED.INC. NEW O.N. ranked by their cash flow conversion efficiency. See U5P operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vera Bradley Inc
NASDAQ:VRA
|
-0.042x |
|
Inpro SA
WAR:INP
|
-0.037x |
|
Fortress Biotech Inc
NASDAQ:FBIO
|
-0.202x |
|
Azaria Rental SOCIMI S.A.
MC:YAZR
|
-0.025x |
|
Brightek Optoelectronic Co Ltd
TW:5244
|
-0.020x |
|
Alcatel Lucent Teletas Telekomunikasyon AS
IS:ALCTL
|
-0.122x |
|
Ahn-Gook Pharmaceutical Co. Ltd
KQ:001540
|
0.086x |
|
VirnetX Holding Corp Common Stock
NYSE:VHC
|
-0.089x |
Annual Cash Flow Conversion Efficiency for VIVANI MED.INC. NEW O.N. (2021–2025)
The table below shows the annual cash flow conversion efficiency of VIVANI MED.INC. NEW O.N. from 2021 to 2025. View VIVANI MED.INC. NEW O.N. stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €15.73 Million ≈ $18.39 Million |
€-24.32 Million ≈ $-28.43 Million |
-1.546x | -30.99% |
| 2024-12-31 | €17.61 Million ≈ $20.59 Million |
€-20.79 Million ≈ $-24.30 Million |
-1.180x | -3.40% |
| 2023-12-31 | €20.76 Million ≈ $24.27 Million |
€-23.70 Million ≈ $-27.71 Million |
-1.142x | -169.22% |
| 2022-12-31 | €44.31 Million ≈ $51.80 Million |
€-18.79 Million ≈ $-21.96 Million |
-0.424x | +90.46% |
| 2021-12-31 | €2.46 Million ≈ $2.88 Million |
€-10.95 Million ≈ $-12.80 Million |
-4.443x | -- |
About VIVANI MED.INC. NEW O.N.
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the t… Read more